Physicians' Academy for Cardiovascular Education

Comparable cardiovascular risk reduction with PCSK9 antibodies and statins

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

Literature - Ference BA, Cannon CP, Landmesser U, et al. - European Heart Journal 2107; published online ahead of print


Data from statin trials and studies with PCSK9 antibodies show that the lipid-lowering therapies reduce the risk of major cardiovascular (CV) events. In this analysis, the results of the PCSK9 antibody trials FOURIER (n=27 564) and SPIRE (n=27 438) were compared with the results of the Cholesterol Treatment Trialists (CTT) meta-analysis of statin trials [1-4].

Main results


PCSK9 antibodies and statins comparably reduce the risk of CV events and slightly increase risk of DM, proportional to the absolute achieved reduction in LDL-C and the total duration of therapy. These data support the focus on LDL-C targets in the prevention of cardiovascular disease.


Show references

Find this article online at European Heart Journal

Share this page with your colleagues and friends: